RegeneRx enrolls first patients in phase 3 US dry eye clinical trial with RGN-259
The primary endpoints of the ARISE-2 trial are the change in ocular discomfort and the change in inferior corneal staining at baseline (prior to first dose) and at
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
The companies formed a clinical trial collaboration to evaluate the combination treatment. The dose-escalation part assessing IPI-549 as a monotherapy in Infinity’s phase 1 trial is continuing, and
ECHELON-2 is a global phase 3 randomized trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in patients with previously untreated CD30-positive mature T-cell